Drugmakers, insurers, hospitals, pharmacies, medical devices, clinical updates, and healthcare business leaders.
A recent market analysis argues that pending regulatory decisions on Moderna’s vaccine pipeline could influence the stock’s next leg, even as the company continues to operate in a post-peak revenue landscape for COVID-era products.
THE APEX TIMES
THE APEX TIMES
A new market piece argues that, when investors grow wary of tech-led risk, large healthcare names such as Johnson & Johnson can look more resilient in the rotation toward defensives.
THE APEX TIMES
A new Yahoo Finance market note casts CVS Health as a stock that could appeal to investors focused on price trends, while offering limited specifics on the fundamental drivers behind that momentum.
THE APEX TIMES
A new market read asks whether Johnson & Johnson’s long-standing appeal as a shareholder dividend story still stacks up, even as investors increasingly weigh payout durability against sector and company-specific risks.
THE APEX TIMES
The retailer-pharmacy chain says it is introducing aluminum packaging for certain CVS Health store-brand over-the-counter medications, while also funding mobile maternal health clinics aimed at underserved communities.
THE APEX TIMES
A market note circulating on Yahoo Finance says Zacks.com users are paying closer attention to UnitedHealth’s stock, prompting investors to re-check what may be driving expectations for the insurer’s near-term performance.
THE APEX TIMES
UnitedHealth Group is taking an advisor role with Optura, a healthcare-focused artificial intelligence startup, according to a report by Yahoo Finance. The startup’s advisory group also includes former top executives from Humana and CVS Health.
THE APEX TIMES
The two companies said they are collaborating to incorporate Charles River’s nonclinical testing services into Lilly’s TuneLab platform, with the goal of aligning testing protocols across organizations involved in drug development.
THE APEX TIMES
Eli Lilly’s top manufacturing executive, Dave Ricks, is credited with steering a roughly $50 billion ramp-up to secure supply for the company’s obesity and diabetes franchise as GLP-1 competition intensifies.
